We found that (a) the global translational rate, measured by puromycin incorporation in vivo, is progressively reduced during the worsening of hepatic steatosis in eIF6+/+ mice (Supplementary Fig. 6a–c), and that at the end of the HFD regimen, eIF6+/− livers had higher levels of puromycin incorporation (Supplementary Fig. 6a–c), and slightly higher polysome/80 S ratio, compared with wt mice. Here, EIF6 is linked to fatty liver disease.